Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
46.22 M
About PhaseBio Pharmaceuticals, Inc.
Sector
CEO
Jonathan P. Mow
Headquarters
Dover
Website
Founded
2002
FIGI
BBG00M1CJ4K2
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Dover, DE.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PHASQ is 0.000001 USD — it hasn't changed in the past 24 hours. Watch PhaseBio Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange PhaseBio Pharmaceuticals, Inc. stocks are traded under the ticker PHASQ.
PhaseBio Pharmaceuticals, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
PHASQ stock is 0% volatile and has beta coefficient of 884.44. Track PhaseBio Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is PhaseBio Pharmaceuticals, Inc. there?
PHASQ earnings for the last quarter are −0.34 USD per share, whereas the estimation was −0.31 USD resulting in a −8.80% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about PhaseBio Pharmaceuticals, Inc. earnings.
PhaseBio Pharmaceuticals, Inc. revenue for the last quarter amounts to 117.00 K USD despite the estimated figure of 3.89 M USD. In the next quarter revenue is expected to reach 1.25 M USD.
Yes, you can track PhaseBio Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
PHASQ stock hasn't changed in a week, the last month showed zero change in price, over the last year PhaseBio Pharmaceuticals, Inc. has showed a 99.86% decrease.
No, PHASQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PHASQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PhaseBio Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
PHASQ reached its all-time high on Apr 9, 2019 with the price of 16.650000 USD, and its all-time low was 0.000001 USD and was reached on Apr 20, 2023. View more price dynamics on PHASQ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PhaseBio Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PhaseBio Pharmaceuticals, Inc. stock shows the sell signal. See more of PhaseBio Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.